Biological Therapy in Treating Patients With Myelodysplastic Syndrome [clinicaltrials:NCT00005853]
Biological Therapy in Treating Patients With Myelodysplastic Syndrome [clinicaltrials:NCT00005853]
Bio2RDF identifier
NCT00005853
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00005853
identifiers.org URI
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
RATIONALE: Biological t ...... ave myelodysplastic syndrome.
brief title [clinicaltrials_vocabulary:brief-title]
Biological Therapy in Treating Patients With Myelodysplastic Syndrome
collaborator [clinicaltrials_vocabulary:collaborator]
completion date [clinicaltrials_vocabulary:completion-date]
2005-08-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
OBJECTIVES:
- ...... ll be accrued for this study.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2000-06-02T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
keyword [clinicaltrials_vocabulary:keyword]
childhood myelodysplastic syndromes
de novo myelodysplastic syndromes
previously treated myelodysplastic syndromes
refractory anemia with excess blasts in transformation
refractory anemia with excess blasts
refractory anemia with ringed sideroblasts
refractory anemia
refractory cytopenia with multilineage dysplasia
secondary myelodysplastic syndromes
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2010-03-31T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00005853
official title [clinicaltrials_vocabulary:official-title]
Therapy of Myelodysplastic Syndrome (MDS) With Antithymocyte Globulin (ATG) and TNFR:Fc
org study id [clinicaltrials_vocabulary:org-study-id]
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2005-08-01T00:00:00Z
secondary id [clinicaltrials_vocabulary:secondary-id]
FHCRC-1478.00
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
1999-12-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2010-03-01T00:00:00Z
identifier
clinicaltrials:NCT00005853
title
Biological Therapy in Treating Patients With Myelodysplastic Syndrome
@en
type
label
Biological Therapy in Treating ...... e [clinicaltrials:NCT00005853]
@en